HIV-1 and immune control: Can we change the course of HIV-1?

Lancet

Volumn 363, Issue 9412, 2004, Pages 833-834

  Kovacs, Andrea ^a   Connors, Mark ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR7;

CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG WITHDRAWAL; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; NOTE; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

EID: 1642381371     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)15770-X     Document Type: Note

References (18)

1. McMichael A.J., Rowland-Jones S.L. Cellular immune responses to HIV-1. Nature. 410:2001;980-987.
2. Rosenberg E.S., Altfeld M., Poon S.H., et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 407:2000;523-526.
3. van Lier R.A., ten Berge I.J., Gamadia L.E. Human CD8(+) T-cell differentiation in response to viruses. Nat Rev Immunol. 3:2003;931-939.
4. Cao Y., Qin L., Zhang L., Safrit J., Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 332:1995;201-208.
5. Migueles S.A., Laborico A.C., Shupert W.L., et al. HIV-1-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol. 3:2002;1061-1068.
6. Lori F., Lewis M.G., Xu J., et al. Control of SIV rebound through structured treatment interruptions during early infection. Science. 290:2000;1591-1593.
7. Haigwood N.L., Watson A., Sutton W.F., et al. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol Lett. 51:1996;107-114.
8. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:1999;708-712.
9. Champagne P., Ogg G.S., King A.S., et al. Skewed maturation of memory HIV-1-specific CD8 T lymphocytes. Nature. 410:2001;106-111.
10. Appay V., Dunbar P.R., Callan M., et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 8:2002;379-385.
11. Wherry E.J., Teichgraber V., Becker T.C., et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 4:2003;225-234.
12. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2:2002;251-262.
13. Lawrence J., Mayers D.L., Hullsiek K.H., et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 349:2003;837-846.
14. Alexander T.H., Ortiz G.M., Wellons M.F., et al. Changes in CD4+ T cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J Acquir Immune Defic Syndr. 34:2003;475-481.
15. Metzner K.J., Bonhoeffer S., Fischer M., et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis. 188:2003;1433-1443.
16. Dybul M., Nies-Kraske E., Daucher M., et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis. 188:2003;388-396.
17. Altfeld M., Allen T.M., Yu X.G., et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature. 420:2002;434-439.
18. Daar E.S., Bai J., Hausner M.A., Majchrowicz M., Tamaddon M., Giorgi J.V. Acute HIV-1 syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion. Ann Intern Med. 128:1998;827-829.